References
- Begg M, Pacher P, Bátkai S et al. Evidence for novel cannabinoid receptors. Pharmacol. Ther.106, 133–145 (2005).
- Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br. J. Pharmacol.147, S163–S171 (2006).
- Di Marzo V, Petrosino S. Endocannabinoids and the regulation of their levels in health and disease. Curr. Opin. Lipidol.18, 129–140 (2007).
- Bisogno T, Di Marzo V. Cannabinoid receptors and endocannabinoids: role in neuroinflammatory and neurodegenerative disorders. CNS Neurol. Disord. Drug Targets9, 564–573 (2010).
- Pacher P, Bátkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacology. Pharmacol. Rev.58, 389–462 (2006).
- Hohmann AG, Suplita RL. Endocannabinoid mechanisms of pain modulation. AAPS J.8, 693–708 (2006).
- Bisogno T, Di Marzo V. The role of the endocannabinoid system in Alzheimer’s disease: facts and hypotheses. Curr. Pharm. Des.14, 2299–2305 (2008).
- Baker D, Pryce G, Croxford JL et al. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J.15, 300–302 (2001).
- Ehrhart J, Obregon D, Mori T et al. Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J. Neuroinflamm.2, 29–32 (2005).
- Ortega-Gutierrez S, Molina-Holgado E, Arévalo-Martín A et al. Activation of the endocannabinoid system as therapeutic approach in a murine model of multiple sclerosis. FASEB J.19, 1338–1340 (2005).
- Mestre L, Correa F, Arevalo-Martin A et al. Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis. J. Neurochem.92, 1327–1339 (2005).
- Ramirez BG, Blázquez C, Gómez del Pulgar T, Guzmán M, de Ceballos ML. Prevention of Alzheimer’s disease pathology by cannabinoids: neuroprotection mediated blockade of microglial activation. J. Neurosci.25, 1904–1913 (2005).
- Carrier EJ, Kearn CS, Barkmeier AJ et al. Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonyl glycerol, which increases proliferation via a CB2 receptor-dependent mechanism. Mol. Pharmacol.65, 999–1007 (2004).
- Maresz K, Carrier EJ, Ponomarev ED et al. Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. J. Neurochem.95, 437–445 (2005).
- Correa F, Docagne F, Mestre L et al. A role for CB2 receptors in anandamide signaling pathways involved in the regulationof IL-12 and IL-23 in microglial cells. Biochem. Pharmacol.77, 86–100 (2009).
- Loria F, Petrosino S, Hernangómez M et al. An endocannabinoid tone limits excitotoxicity in vitro and in a model of multiple sclerosis. Neurobiol. Dis.37, 166–176 (2010).
- Centonze D, Bari M, Rossi S et al. The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis. Brain130, 2543–2553 (2007).
- Russo E, Guy GW. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med. Hypotheses66, 234–246 (2006).
- Bisogno T, Hanus L, De Petrocellis L et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br. J. Pharmacol.134, 845–852 (2001).
- Hilliard A, Stott C, Wright S et al. The evaluation of Sativex (THC:CBD) on the inhibition of spasticity in an experimental model of multiple sclerosis. Presented at: European Committee for Treatment and Research in Multiple Sclerosis. Gothenburg, Sweden, 15 October 2010.